The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer
Abstract
BACKGROUND: The value of nephrectomy in metastatic renal-cell cancer has long been debated. Several nonrandomized studies suggest a higher rate of response to systemic therapy and longer survival in patients who have undergone nephrectomy. METHODS: We randomly assigned patients with metastatic renal-cell cancer who were acceptable candidates for nephrectomy to undergo radical nephrectomy followed by therapy with interferon alfa-2b or to receive interferon alfa-2b therapy alone. The primary end point was survival, and the secondary end point was a response of the tumor to treatment. RESULTS: The median survival of 120 eligible patients assigned to surgery followed by interferon was 11.1 months, and among the 121 eligible patients assigned to interferon alone it was 8.1 months (P=0.05). The difference in median survival between the two groups was independent of performance status, metastatic site, and the presence or absence of a measurable metastatic lesion. CONCLUSIONS: Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferon therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 610
Figlin, R. A., Thompson, J. A., Bukowski, R. M., Vogelzang, N. J., Novick, A. C., Lange, P., Steinberg, G. D., & Belldegrun, A. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2521 · Cited by 212
CYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA
Yagoda, A., Petrylak, D., & Thompson, S. (1993) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00489-4 · Cited by 207
Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas
Nishiyama, K., Shirahama, T., Yoshimura, A., Sumizawa, T., Furukawa, T., Ichikawa, M., Akiyama, S.-I., & Ohi, Y. (1993) · Cancer · Cited by 45
Cited by
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Rini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., Ritchie, A. W. S., Attard, G., Chowdhury, S., Cross, W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32486-3 · Cited by 1,262
Capitanio, U., & Montorsi, F. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00046-x · Cited by 1,014
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J.-B., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., Cormier, L., Lang, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803675 · Cited by 946
Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis
FLANIGAN, R. C., MICKISCH, G., SYLVESTER, R., TANGEN, C., VAN POPPEL, H., & CRAWFORD, E. D. (2004) · Journal of Urology · doi:10.1097/01.ju.0000110610.61545.ae · Cited by 872
Self-citationLeibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., Weaver, A. L., Parker, A. S., & Zincke, H. (2003) · Cancer · doi:10.1002/cncr.11234 · Cited by 837
Treatment of renal cell carcinoma: Current status and future directions
Barata, P. C., & Rini, B. I. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21411 · Cited by 831
MicroRNA Signature Predicts Survival and Relapse in Lung Cancer
Yu, S.-L., Chen, H.-Y., Chang, G.-C., Chen, C.-Y., Chen, H.-W., Singh, S., Cheng, C.-L., Yu, C.-J., Lee, Y.-C., Chen, H.-S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.008 · Cited by 783
Fujitani, K., Yang, H.-K., Mizusawa, J., Kim, Y.-W., Terashima, M., Han, S.-U., Iwasaki, Y., Hyung, W. J., Takagane, A., Park, D. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00553-7 · Cited by 712
Zisman, A., Pantuck, A. J., Wieder, J., Chao, D. H., Dorey, F., Said, J. W., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.05.111 · Cited by 675
Jonasch, E., Gao, J., & Rathmell, W. K. (2014) · BMJ · doi:10.1136/bmj.g4797 · Cited by 636
Immunotherapy for advanced renal cell cancer
Coppin, C., Porzsolt, F., Autenrieth, M., Kumpf, J., Coldman, A., & Wilt, T. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001425.pub2 · Cited by 589
RetractedKidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Bhayani, S., Bro, W. P., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Fishman, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0100 · Cited by 571
Boevé, L. M. S., Hulshof, M. C. C. M., Vis, A. N., Zwinderman, A. H., Twisk, J. W. R., Witjes, W. P. J., Delaere, K. P. J., Moorselaar, R. J. A. V., Verhagen, P. C. M. S., & van Andel, G. (2019) · European Urology · doi:10.1016/j.eururo.2018.09.008 · Cited by 571
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
“IFN-α produced variable results in patients with metastatic renal cell carcinoma (Amato 1999; Gollob et al. 2000; Flanigan et al. 2001).”
BackgroundBex, A., Mulders, P., Jewett, M., Wagstaff, J., van Thienen, J. V., Blank, C. U., van Velthoven, R., del Pilar Laguna, M., Wood, L., van Melick, H. H. E., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5543 · Cited by 492
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Aparicio, A. M., Harzstark, A. L., Corn, P. G., Wen, S., Araujo, J. C., Tu, S.-M., Pagliaro, L. C., Kim, J., Millikan, R. E., Ryan, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3791 · Cited by 479
Motzer, R. J., Agarwal, N., Beard, C., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S. L., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0043 · Cited by 470
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
Gene Signatures of Progression and Metastasis in Renal Cell Cancer
Jones, J., Otu, H., Spentzos, D., Kolia, S., Inan, M., Beecken, W. D., Fellbaum, C., Gu, X., Joseph, M., Pantuck, A. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2225 · Cited by 447
Culp, S. H., Schellhammer, P. F., & Williams, M. B. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.012 · Cited by 434
Pagani, O., Senkus, E., Wood, W., Colleoni, M., Cufer, T., Kyriakides, S., Costa, A., Winer, E. P., Cardoso, F., & on behalf of the ESO-MBC Task Force (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq029 · Cited by 422
Rini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Rapiti, E., Verkooijen, H. M., Vlastos, G., Fioretta, G., Neyroud-Caspar, I., Sappino, A. P., Chappuis, P. O., & Bouchardy, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2226 · Cited by 391
Does aggressive local therapy improve survival in metastatic breast cancer?
Khan, S. A., Stewart, A. K., & Morrow, M. (2002) · Surgery · doi:10.1067/msy.2002.127544 · Cited by 391
Rini, B. I., Campbell, S. C., & Rathmell, W. K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000219260.60714.c4 · Cited by 379
Soran, A., Ozmen, V., Ozbas, S., Karanlik, H., Muslumanoglu, M., Igci, A., Canturk, Z., Utkan, Z., Ozaslan, C., Evrensel, T., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6494-6 · Cited by 342
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
Rathmell, W. K., Rumble, R. B., Van Veldhuizen, P. J., Al-Ahmadie, H., Emamekhoo, H., Hauke, R. J., Louie, A. V., Milowsky, M. I., Molina, A. M., Rose, T. L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00868 · Cited by 336
Gnerlich, J., Jeffe, D. B., Deshpande, A. D., Beers, C., Zander, C., & Margenthaler, J. A. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9438-0 · Cited by 328
The biology and treatment of oligometastatic cancer
Reyes, D. K., & Pienta, K. J. (2015) · Oncotarget · doi:10.18632/oncotarget.3455 · Cited by 320
Cook, A. D., Single, R., & McCahill, L. E. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.06.012 · Cited by 297
Babiera, G. V., Rao, R., Feng, L., Meric-Bernstam, F., Kuerer, H. M., Singletary, S. E., Hunt, K. K., Ross, M. I., Gwyn, K. M., Feig, B. W., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.03.033 · Cited by 284
Ruo, L., Gougoutas, C., Paty, P. B., Guillem, J. G., Cohen, A. M., & Wong, D. W. (2003) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(03)00136-4 · Cited by 277
Heidenreich, A., Pfister, D., & Porres, D. (2015) · Journal of Urology · doi:10.1016/j.juro.2014.09.089 · Cited by 268
Checkpoint inhibitor immunotherapy in kidney cancer
Xu, W., Atkins, M. B., & McDermott, D. F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0282-3 · Cited by 261
Association of Surgery With Improved Survival in Stage IV Breast Cancer Patients
Blanchard, D. K., Shetty, P. B., Hilsenbeck, S. G., & Elledge, R. M. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e3181656d32 · Cited by 254
Interferons: role in cancer therapy
Abdolvahab, M. H., Darvishi, B., Zarei, M., Majidzadeh-A, K., & Farahmand, L. (2020) · Immunotherapy · doi:10.2217/imt-2019-0217 · Cited by 50
Metadata
- Authors
- Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N., & Crawford, E. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-12-06
- Volume
- 345
- Issue
- 23
- Pages
- 1655-1659
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2021256410
- Cited by
- 1,715
- References
- 6
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.